市場調查報告書
商品編碼
1423674
2030 年服務實驗室市場預測:按服務類型、應用和地區分類的全球分析Service Laboratory Market Forecasts to 2030 - Global Analysis By Service Type, By Application and By Geography |
根據 Stratistics MRC 的數據,全球服務實驗室市場在預測期內將以 7.2% 的複合年成長率成長。
服務實驗室涉及使用專用設備來監測醫療環境中電離輻射水平的測量和檢測。這些設備透過追蹤輻射暴露、評估 X 光、 電腦斷層掃描和放射治療等治療期間的劑量以及保護患者和醫護人員免受潛在的輻射過度暴露來幫助確保安全。我會確保安全。
根據疾病管制中心的數據,每年進行 140 億次實驗室檢測。據估計,70% 的醫療決定是基於實驗室測試結果。
診斷測試需求增加
隨著人們對預防性醫療保健和疾病早期檢測的日益關注,對準確和先進的診斷測試的需求日益成長。人口老化、慢性病增加、診斷工具技術進步等因素導致需求激增。因此,服務實驗室透過增加對各種診斷測試的需求並滿足醫療保健及相關行業對準確、及時和全面的診斷服務日益成長的需求來推動市場成長。
營運和資本成本高
它們需要最尖端科技、專業設備、熟練的人員,並嚴格遵守監管標準,導致營運成本高昂。此外,建立和維護最先進的實驗室的初始投資也會增加您的資本成本。這些高昂的營運和資本成本給進入市場的中小企業帶來了挑戰,限制了它們的競爭力和創新投資能力。
個性化醫療的興起
個人化醫療依賴於基於個人基因組成、生活方式和特定健康特徵的精確診斷測試和客製化治療。這一趨勢刺激了對基因檢測、生物標記分析和分子診斷等先進檢測服務的需求,這些服務需要專門的實驗室。個人化醫療服務實驗室可以提供全面的檢測服務,支援醫療保健提供者提供更有效、更有針對性的治療,從而促進個人化醫療的發展,擴大服務實驗室市場的機會。
不斷的技術進步
快速的技術發展可能會使現有設備和方法過時,需要頻繁升級和投資新技術。這種不斷適應和創新的需求給實驗室帶來了保持競爭力的財務壓力。此外,快速的變更可能會在更新的系統和舊有系統系統之間造成差距,影響檢查程序的標準化和一致性,並迫使服務供應商採用新技術和服務。在確保連續性和可靠性之間保持平衡是一個潛在的挑戰。
COVID-19 的疫情對服務實驗室市場產生了重大影響,並導致診斷測試服務的需求增加。世界各地的實驗室設施面臨檢測病毒的測試要求激增,導致業務挑戰、供應鏈中斷和勞動力限制。此外,疫情加速了研究和開發活動,並凸顯了服務實驗室在疾病診斷、治療開發和公共衛生應對策略中的重要性。
預計常規測試部分在預測期內將是最大的
預計常規測試行業在預測期內將成長最大,這主要是由於其在各個行業和日常流程中的廣泛應用。製藥、食品和飲料和飲料以及製造業等行業都嚴重依賴常規測試來確保品質和遵守法規。因此,對常規和標準化測試程序的持續需求使得常規測試部分在預測期內成為廣泛測試服務市場的主導和最大貢獻者。
預計臨床測試領域在預測期內複合年成長率最高
由於醫療保健支出的增加、預防醫學意識的增強以及慢性病的增加正在推動對臨床實驗室服務的需求,預計臨床實驗室產業將在預測期內實現最高成長率。此外,診斷技術的進步以及對早期疾病檢測和個人化醫療的關注正在推動對全面臨床檢測的需求。總的來說,這些因素正在推動臨床檢測產業的擴張,顯示醫療保健產業的強勁成長潛力。
北美擁有先進的醫療基礎設施並促進了對診斷和測試服務的高需求,因此能夠主導市場。此外,隨著製藥和生物技術領域的強大,對專業實驗室分析的需求也不斷增加。此外,嚴格的監管標準需要全面的測試,進一步推動了對服務實驗室的需求。主要產業參與者的存在、技術進步以及對研發的重視使得北美在服務實驗室產業中佔據了最大的市場佔有率。
由於快速的工業化、技術進步以及醫療保健和製藥等領域的研發活動的活性化,預計亞太地區的市場將顯著成長。此外,嚴格的品質標準、快速成長的人口趨勢以及產業外包趨勢都推動了對實驗室委託服務的需求。該地區不斷發展的經濟和對創新的重視使該地區成為服務實驗室的重要中心,推動了市場的顯著成長。
According to Stratistics MRC, the Global Service Laboratory Market is growing at a CAGR of 7.2% during the forecast period. Service Laboratory involves the use of specialised devices to monitor measure and detect ionising radiation levels in medical settings. These instruments ensure safety by tracking radiation exposure, assessing dosage during treatments like X-rays, CT scans or radiation therapy and safeguarding both patients and healthcare professionals from potential overexposure to radiation.
According to the Centers for Disease Control, 14 billion lab tests are conducted annually. It is estimated 70% of medical decisions are based on lab test results.
Increasing demand for diagnostic testing
With a growing focus on preventive healthcare and early disease detection, there's an increased need for accurate and advanced diagnostic tests. Factors like an aging population, escalating incidences of chronic diseases and technological advancements in diagnostic tools contribute to this demand surge. Consequently, service laboratories experience heightened requests for a diverse range of diagnostic tests, driving market growth as they cater to the escalating need for precise, timely and comprehensive diagnostic services across healthcare and related industries.
High operational and capital costs
The need for cutting-edge technology, specialised equipment, skilled personnel and stringent compliance with regulatory standards leads to substantial operational expenses. Additionally, the initial investment in setting up and maintaining state-of-the-art laboratories adds to the capital costs. These high operational and capital expenses can pose challenges for smaller players entering the market, limiting their ability to compete and invest in innovation.
Rise in personalized medicine
Personalised medicine relies on precise diagnostic tests and tailored treatments based on an individual's genetic makeup, lifestyle and specific health characteristics. This trend fuels the demand for advanced testing services, including genetic testing, biomarker analysis and molecular diagnostics, requiring specialised laboratories. Service laboratories catering to personalised medicine can offer comprehensive testing services, supporting healthcare providers in delivering more effective, targeted treatments, thereby driving the growth of personalised medicine and expanding opportunities within the service laboratory market.
Continuous technological advancements
Rapid technological evolution might render existing equipment or methodologies obsolete, necessitating frequent upgrades or investments in new technology. This constant need for adaptation and innovation places financial pressure on laboratories to stay competitive. Moreover, the rapid pace of change could create a gap between updated and legacy systems, impacting standardisation and consistency in testing procedures and potentially challenging service providers to maintain a balance between adopting new technologies and ensuring continuity and reliability in their services.
The COVID-19 pandemic significantly affected the service laboratory market, triggering increased demand for diagnostic testing services. Laboratories worldwide faced a surge in testing requirements for virus detection, leading to operational challenges, supply chain disruptions and workforce constraints. Additionally, the pandemic accelerated research and development activities, emphasising the importance of service laboratories in disease diagnosis, treatment development and public health response strategies.
The routine testing segment is expected to be the largest during the forecast period
The routine testing segment is anticipated to be the largest during the forecast period, primarily owing to its widespread application across various industries and everyday processes. Industries such as pharmaceuticals, food and beverage and manufacturing heavily rely on routine testing for quality assurance and regulatory compliance. As a result, the consistent demand for regular, standardised testing procedures positions the routine testing segment as the dominant and largest contributor to the broader testing services market during the forecast period.
The clinical testing segment is expected to have the highest CAGR during the forecast period
The clinical testing segment is projected to achieve the highest growth rate during the forecast period owing to increasing healthcare expenditure, growing awareness about preventive healthcare and a rise in chronic diseases, which drive the demand for clinical testing services. Moreover, advancements in diagnostic technologies, coupled with a focus on early disease detection and personalised medicine, propel the need for comprehensive clinical testing. These factors collectively fuel the expansion of the clinical testing segment, indicating robust growth potential in the healthcare industry.
North America is positioned to dominate the market due to the region's advanced healthcare infrastructure, which fosters a high demand for diagnostic and testing services. Additionally, a robust pharmaceutical and biotechnology sector drives the need for specialised laboratory analyses. Moreover, stringent regulatory standards necessitate comprehensive testing, further boosting the demand for service laboratories. The presence of major industry players, technological advancements and a strong emphasis on research and development collectively contribute to North America's largest market share in the service laboratory industry.
The Asia-Pacific region anticipates significant growth in the market due to rapid industrialization, technological advancements and increasing research and development activities across sectors like healthcare and pharmaceuticals. Additionally, stringent quality standards, a burgeoning population and the outsourcing trend in industries fuel the need for outsourced laboratory services. This region's expanding economies and the emphasis on innovation position it as a key hub for service laboratories, fostering substantial market growth.
Key players in the market
Some of the key players in Service Laboratory Market include Abbott Laboratories, ACM Global Laboratories, Agilent Technologies, Beckman Coulter, BioReference Laboratories, Bruker Corporation, Charles River Laboratories, Eurofins Scientific, Genomic Health, Labcorp, NeoGenomics Laboratories, PerkinElmer, Qiagen NV, Quest Diagnostics, Roche Diagnostics, Siemens Healthineers, Sonic Healthcare, SYNLAB International GmbH, Thermo Fisher Scientific and Waters Corporation.
In June 2023, IMCD inaugurated an additional facility close to Philadelphia. To better serve its clients in North America, IMCD announced the relocation and opening of its "IMCD Coatings & Construction Laboratory.
In June 2022, Labcorp, a paramount global life sciences company, announced the expansion of CB Trial Laboratory, the central laboratory shared by Labcorp Drug Development and BML, a top Japanese provider of clinical laboratory testing services, to strengthen its central laboratory presence and drug development capabilities in Japan.